You are here

Article Text

Article menu
Download PDFPDF
Case report
Corticosteroids for pulmonary lymphangitic carcinomatosis
  1. Takayuki Takimoto
  1. Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan
  1. Correspondence to Dr Takayuki Takimoto, Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, 591-8555, Japan; takimoto.takayuki.ra{at}mail.hosp.go.jp

Abstract

Pulmonary lymphangitic carcinomatosis (PLC) is a type of lymphangitic spread of cancer cells, from a primary site to the pulmonary vasculature and lymphatics. Corticosteroids are recommended for PLC by clinical guidelines, although scientific evidence for this traditional practice is still lacking. We report a patient with lung cancer who developed clinically diagnosed PLC and was successfully treated with steroid treatment. The pulmonary shadows suggestive of PLC were remarkably improved, as well as her symptom. Corticosteroids are worth trying when PLC is clinically suspected.

  • Supportive care
  • Dyspnoea
  • Lymphoedema
  • Lung

https://doi.org/10.1136/spcare-2022-003983

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.